Novartis: FDA grants second priority review to leukemia drug
(CercleFinance.com) - Swiss pharma giant Novartis said the US Food and Drug Administration (FDA) has granted priority review to its immuno-cellular therapy Kymriah for adults with relapsed or refractory diffuse large B-cell lymphoma.
The FDA's decision marks the second priority review granted to Kymriah after the leukaemia drug became the first CAR-T cell therapy to receive regulatory approval in August 2017.
Kymriah uses a patient's own T cells to fight cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The FDA's decision marks the second priority review granted to Kymriah after the leukaemia drug became the first CAR-T cell therapy to receive regulatory approval in August 2017.
Kymriah uses a patient's own T cells to fight cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.